Enveda Biosciences is a biotechnology company that leverages artificial intelligence and computational chemistry to discover and develop natural compounds for therapeutic use. The company's platform aims to accelerate drug discovery by identifying novel therapeutic candidates from the vast chemical space of natural products.

Enveda Biosciences

AvengeBio was a biotechnology company that is now permanently closed.

AvengeBio

Kebotix provides R&D solutions through enterprise AI customized for materials discovery, leveraging cloud technologies, machine learning, and automation.

Kebotix

At Enveda, we are systematically translating molecules found in medicinal plants into new drugs for challenging diseases. Our platform harnesses nature's complexity with the help of cutting-edge advancements in knowledge graphs, machine learning, and metabolomics.

Hannah Gordon, PhD, MSCI is excited to be presenting the data on our latest assets at the MassBio 2024 Align Summit with insights by McKinsey & Company and Locust Walk on April 25. You can register to hear her talk here: https://lnkd.in/euynZvkA   

#AlignSummit24 #AlignSummit #AIDrugDiscovery  

We're hosting an Open House! On Wednesday, May 29th from 4-6 PM, come explore our brand new lab and office space as we showcase the latest in bioscience innovation. Join us for an tour of our facilities located at 5700 Flatiron Pkwy, Boulder, CO 80301

Don't miss special presentations from our founder and CEO, Viswa Colluru, PhD and the CEO of the Colorado BioScience Association, Elyse Blazevich. Refreshments will be served as we celebrate collaboration and advancement within the Colorado bioscience community. RSVP now and mark your calendars for an event you won't want to miss! 🗓️

RSVP here: 
https://lnkd.in/e22YBfw4

#EnvedaOpenHouse #Innovation #BioscienceCommunity

Envedians Hannah Gordon, PhD, MSCI, and Joseph P. will be attending the 2024 Align Summit organized by MassBio, McKinsey & Company, and Locust Walk on April 25 at the Royal Sonesta Hotel in Boston. Hannah, our Chief Product Officer, will be presenting our latest data on two of our lead molecules that demonstrate the flexibility of our platform for discovering molecules with novel MOAs and for known targets. Register to hear her talk here: https://lnkd.in/euynZvkA 

At Enveda, we are proud to be part of the growing biotech community in Boulder. Our new HQ at Flatiron Park was featured on CNBC, and you can learn more about what makes Boulder one of the 'Cities of Success' here: https://lnkd.in/gee7WUi3

#Enveda #Boulder #LifeSciences #CNBCFeature #biotech #innovation

Metric
Company Name	Enveda Biosciences	AvengeBio	Kebotix
Symbol
MSH ID	COM:ENVEDABIO	COM:AVENGEBIO	COM:KEBOTIX
Market	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services	Technology
Industry	Biotechnology	Biotechnology	Materials Science
Country	US	US	US
Stage
Employee Count	236	11
Website	envedabio.com	avengebio.com	kebotix.com
LinkedIn	envedabio
Founders

Metric
Market Cap	151M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score	94.96
28-Day Growth Score	22.24
90-Day Growth Score	17.85
365-Day Growth Score	42.40

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:ENVEDABIO

Enveda Biosciences

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue